Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis.
Priyanka AnandSebastian G SchneeweissArash MostaghimiMaria C SchneeweissPublished in: Pharmacoepidemiology and drug safety (2022)
Among new users of a systemic treatment for AD, dupilumab was most used treatment by far. This article is protected by copyright. All rights reserved.
Keyphrases